Kamada Ltd. is a global biopharmaceutical company specializing in plasma-derived protein therapeutics for rare and serious conditions, with a commercial portfolio that includes six FDA-approved products such as GLASSIA, KEDRAB, and CYTOGAM, distributed primarily through its U.S. subsidiary. The company operates three plasma collection centers in Texas and generates revenue through direct sales of proprietary and acquired plasma-derived therapies, royalty income from partnerships including a long-term agreement with Takeda Pharmaceuticals, plasma supply to other manufacturers, and distribution of pharmaceutical products in Israel and the MENA region. Its growth strategy centers on expanding its commercial product portfolio through life-cycle management and strategic acquisitions, scaling plasma collection operations to support internal and external demand, and pursuing partnerships and business development opportunities to strengthen its competitive position in specialty plasma therapeutics.